Atara biotherapeutics announces proposed offering of common stock

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a pioneer in t-cell immunotherapy leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. in connection with the proposed offering, atara biotherapeutics ex
ATRA Ratings Summary
ATRA Quant Ranking